Cellectar broadens global manufacturing network in preparation for potential commercialization of Iopofosine I 131 in 2025.

Vesalius Therapeutics, a company pioneering a revolutionary platform to deliver breakthrough treatments for common diseases, ...

GSK is paying $80 million to ink a multi-target neurodegenerative pact with Flagship-founded Vesalius Therapeutics that ...

CERo Therapeutics stock is rising higher on Monday as investors react to the latest preclinical data concerning lead compound ...

DNA-testing company 23andMe Holding Co. will slash its workforce by about 40% and discontinue its therapeutics program as ...

The platform also features a rapid, five-day manufacturing process that significantly improves production efficiency while ...

Goodwin is presenting a two-part publication series covering life sciences trends involving license deals, M&A, and financing for Greater China’s ...

CERo Therapeutics (CERO) announces the presentation of preclinical data demonstrating the capability of its lead compound CER-1236 to kill ...

In the press release, AbbVie said the following: In addition to emraclidine, through the Cerevel acquisition AbbVie gained a ...